TOYOTA GAZOO Racing Heading Home to Fuji

TOKYO, Sep 5, 2022 - (JCN Newswire via SEAPRWire.com) - TOYOTA GAZOO Racing's GR010 HYBRID Hypercar will make its home debut when the FIA World Endurance Championship (WEC) returns to Japan for the 6 Hours of Fuji after a three-year absence.The penultimate round of the 2022 WEC season sees the series return to Fuji Speedway, located 100km west of Tokyo, for the first time since October 2019 and TOYOTA GAZOO Racing targets a fifth consecutive victory on its home track. Close competition over the first four races of the season sees TOYOTA GAZOO Racing lead the manufacturers' standings by 15 points from Alpine following a dramatic 6 Hours of Monza in July. The 2022 Le Mans winners Sebastien Buemi, Brendon Hartley and Ryo Hirakawa, in the #8 GR010 HYBRID, were runners-up in Italy and are second in the drivers' championship, 10 points behind the leading Alpine crew. Reigning champions Mike Conway, Kamui Kobayashi and Jose Maria Lopez finished third at Monza after having contact with another car whilst leading the race, and they aim for a second win of the year in their #7 GR010 HYBRID. Both Kamui and Ryo have already raced at Fuji Speedway this year, in Super Formula. Ryo won the season-opening race there in April to add to his Super GT victory there in 2020. The GR010 HYBRID will race for the first time in front of Japanese fans and partners this weekend, although the 2021 Le Mans-winning example has been exhibited around the country since it made history by becoming the first Hypercar to win at La Sarthe. Fuji Speedway is more than a home race for the team. The hybrid powertrain in the GR010 HYBRID is designed, developed and built just a few kilometres from the track and, for many colleagues from Higashi-Fuji Technical Center, this weekend's race is their first chance to see the car in action. The 4.563km track, which is the shortest on the WEC calendar despite its 1.5km start-finish straight, is also the most successful circuit for TOYOTA GAZOO Racing, which has won seven of the eight WEC races, missing out on the top step of the podium only in a difficult 2015 season. Historically, Fuji Speedway played a significant role in Toyota's endurance racing development. The iconic 2000GT sportscar showed its speed with wins in the 1967 24-hour and 1000km races, whilst the Toyota 7 wrote itself into legend with fearsome performances there, including victories in the Fuji 1000km in 1968 and 1969. The All Japan Sports Prototype Championship, a national series for Le Mans-style cars, brought Toyota back into front-line sportscar competition in the 1980s and it became a regular winner at Fuji Speedway, which also hosted Japan's first World Sportscar Championship race in 1982. The circuit, on the foothills of Mount Fuji, was upgraded in 2005 and, while the track lay-out remains unchanged since the first modern WEC race there in 2012, the surroundings will look different thanks to the development of a new motorsport resort, including museum, driving centre, visitor entertainment and hotel. The always-enthusiastic Japanese fans get their first chance to see the Hypercars at Fuji Speedway on Friday, when two 90-minute practice sessions are scheduled. Final practice on Saturday prepares the teams for an early afternoon qualifying, while the race begins at 11am local time on Sunday, 4am CEST.For more information, visit https://toyotagazooracing.com/wec/release/2022/rd05-preview/. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

ROOKIE Racing and TOM’S SPIRIT Announce Team Setups for Super Taikyu Series Fuji 24 Hours Race

Toyota City, Japan, May 20, 2022 - (JCN Newswire via SEAPRWire.com) - ROOKIE Racing, Inc., TOM'S SPIRIT Co., Ltd., and TOYOTA GAZOO Racing have announced their team setups for the ENEOS Super Taikyu Series 2022 Powered by Hankook Round 2 NAPAC Fuji SUPER TEC 24 Hours Race (Fuji 24 Hours Race) to be held from June 3 to 5.For the Fuji 24 Hours Race, TOYOTA GAZOO Racing WRT team principal Jari-Matti Latvala, Japan Rally Championship racer Norihiko Katsuta, and SUPER GT and Japanese Super Formula Championship racer Yuhi Sekiguchi have been designated as one-time drivers for ORC ROOKIE Racing.Also, by actively disseminating information aimed at Asia, TGR and its partners intend to provide maximum support for the Super Taikyu Organization's desire to make the Super Taikyu Series recognized throughout Asia.Jari-Matti Latvala"When I saw the live video of a Super Taikyu 24-hour race in Fuji during last year's Rally Portugal, I thought that Toyota's new approach to carbon neutrality was simply amazing. I agree that sound is one of the best parts of motorsports. And I heard from (TGR FIA World Endurance Championship Team Principal and driver) Kamui Kobayashi and (TGR Europe Vice Chairman) Kazuki Nakajima that the feeling of driving the car is the same as a gasoline engine car. I was really interested in their feedback so I wanted to check it for myself, and I will have the chance to drive this car. Having experienced firsthand the activities toward carbon neutrality, I would like to share them with the world, especially in Europe. And I want to check the potential of this technology for rally cars. I'm happy that I can come to Japan before this year's Rally Japan. See you at Fuji Speedway!" Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries

TOKYO, Aug 31, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand. This agreement conclusion will lead to an expansion into Southeast Asia of an agreement regarding dotinurad in China concluded by Eisai and FUJI YAKUHIN in February 2020.Based on this agreement, Eisai will acquire exclusive development and marketing rights for dotinurad in the said five countries from FUJI YAKUHIN. FUJI YAKUHIN will retain responsibility for manufacturing the formulation of dotinurad, and supply to Eisai. Eisai will be responsible for New Drug Applications for dotinurad in the said five countries and pay FUJI YAKUHIN an upfront payment and sales milestones.Hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout. Furthermore, it is estimated that currently in Southeast Asia, the number of hyperuricemia and gout patients is approximately 2.83 million.(1) It is expected that the number of patients will further increase in the near future due to changes in lifestyle and dietary preferences in accordance with socioeconomic development in Southeast Asia.Dotinurad is a new therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. Dotinurad suppresses uric acid reabsorption and lowers blood uric acid levels, by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney. In Japan, FUJI YAKUHIN obtained manufacturing and marketing approval for dotinurad in January 2020 and launched it in May 2020.Under this agreement, Eisai will proceed with the development and commercialization of dotinurad in the said five countries, and aim to contribute to patients with unmet medical needs in Southeast Asia. FUJI YAKUHIN anticipates maximizing the value of dotinurad in Asia by leveraging Eisai's business base.Through the development and commercialization of dotinurad, Eisai and FUJI YAKUHIN will provide new treatment options for hyperuricemia and gout in the said five countries in addition to China, and contribute to improving the quality of life of patients in Asia. About Eisai Co., Ltd.Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. Eisai defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology.In the spirit of hhc, Eisai takes that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.For further information on Eisai Co., Ltd., please visit https://www.eisai.com and connect with us on Twitter @Eisai_SDGs.About FUJI YAKUHIN CO., LTD.FUJI YAKUHIN was founded in 1930 as a distributor of placement drugs, and is now a diversified pharmaceutical company that operates drugstores and dispensing pharmacies, pharmaceutical manufacturing, pharmaceutical research and development, and prescription drug sales in addition to its placement drug sales business.The Group applies its 1,360 drugstores centering on SEIMS, in addition to a comprehensive nationwide network of placement drug as well as pharmaceutical research and development and manufacturing capabilities, and aims to realize a society in which everyone can lead an abundant life by supporting people in every aspect of their lives and continuing to deliver wellness to them daily.In the prescription drug research and development business, the Group created two drugs with different mechanisms of action for the treatment of gout and hyperuricemia, topiroxostat (product name: TOPILORIC Tablets) and dotinurad (product name: URECE Tablets). With regard to dotinurad, we are working on licensing activities with the aim of contributing to patients around the world who require treatment for gout and hyperuricemia.For further information on FUJI YAKUHIN CO., LTD., please visit https://www.fujiyakuhin.co.jp/ (Japanese only)About dotinuradDotinurad is a therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. Dotinurad selectively inhibits URAT1, one of the uric acid transporters, thus preventing reabsorption of uric acid by the kidneys and promoting uric acid excretion in the urine. In addition, it has a small effect on other transporters affecting uric acid secretion, so it reduces serum uric acid levels at lower doses. Dotinurad is expected to have a low risk of side effects and drug interaction. In Japan, FUJI YAKUHIN obtained manufacturing and marketing approval for dotinurad in January 2020 and launched it in May 2020.(1) Saeid Safiri et al., Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017, American College of Rheumatology, 2020 Nov; 72: 1916-1927.Media InquiriesEisai Co., Ltd.Public Relations Department TEL: +81-(0)3-3817-5120 Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)